← Leaderboards
Vahakn B Shahinian
University Of Michigan At Ann Arbor
$9,253,721
Attributed
$19,251,695
Total exposure
14
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.4M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$14,366,834 · 11
AHRQ$4,884,861 · 3
By mechanism
R01$17,175,037 · 11
T32$977,017 · 1
R34$577,585 · 1
TL1$522,056 · 1
Top collaborators
- Brent K. Hollenbeck25 shared
- John Malcolm Hollingsworth11 shared
- Richard A Hirth8 shared
- Chandy Skaria Ellimoottil3 shared
- Ganesh S Palapattu3 shared
- Andrew M Ryan2 shared
- Anne Evelyn Sales2 shared
Most similar at University Of Michigan At Ann Arbor
Same institution · by research overlap
- John Malcolm Hollingsworth$8,254,178
- Ramon R Diaz-Arrastia$21,608,850
- Toni Claudette Antonucci$18,648,801
- Kayte Kelleher Spector-Bagdady$2,744,468
- Richard A Hirth$9,054,960
Others in their field
Top investigators on “Medicare”
- David R. Weir · University Of Michigan At Ann Arbor$380,546,860
- Robert J Willis · University Of Michigan At Ann Arbor$79,645,109
- Judith Kasper · Johns Hopkins University$77,526,591
- Vicki A. Freedman · Madlyn/Leonard Abramson Ctr/Jewish Life$59,405,180
- Daniel Ernest Ford · Johns Hopkins University$56,884,093
- Keri Hammel · The Emmes Company, Llc$53,700,408
Research focus
MedicareCaringMalignant Neoplasm Of ProstateFinancial IncentiveProviderCostUrologistPhysiciansUrologyMalignant NeoplasmsUncertaintyInterestVariantEnsureCancer CareHeterogeneityMonitorIncentivesRecommendationPaymentAffectTrendImageAdherence
Grant awards (46)
Physician dispensing of oral specialty drugs for advanced prostate cancer and its implications for patients$1,411,059
R01 · FY2025 · CA
Aligning financial incentives to promote rational use of active surveillance for prostate cancer$663,204
R01 · FY2025 · CA · contact PI
Leveraging the ESRD Treatment Choices model to understand the benefits of home versus in-center dialysis$660,010
R01 · FY2025 · DK · contact PI
Urology practice consolidation and care for men with prostate cancer$585,584
R01 · FY2025 · CA · contact PI
Advanced Training in Urologic Oncology$411,359
T32 · FY2025 · CA
Effects of integration of advanced practice providers into surgical group practice$391,216
R01 · FY2025 · HS
Planning to implement high-quality active surveillance in new-onset favorable risk prostate cancer$250,089
R34 · FY2025 · CA
Leveraging the ESRD Treatment Choices model to understand the benefits of home versus in-center dialysis$633,610
R01 · FY2024 · DK · contact PI
Urology practice consolidation and care for men with prostate cancer$593,112
R01 · FY2024 · CA · contact PI
Real-world effectiveness of preventive pharmacological therapy for patients with kidney stones$546,833
R01 · FY2024 · DK · contact PI
Aligning financial incentives to promote rational use of active surveillance for prostate cancer$451,145
R01 · FY2024 · CA · contact PI
Physician dispensing of oral specialty drugs for advanced prostate cancer and its implications for patients$400,622
R01 · FY2024 · CA
Primary care involvement in End Stage Renal Disease Seamless Care Organizations (ESCOs) and the quality and costs of care for patients on chronic dialysis$399,999
R01 · FY2024 · HS · contact PI
Effects of integration of advanced practice providers into surgical group practice$396,696
R01 · FY2024 · HS
Planning to implement high-quality active surveillance in new-onset favorable risk prostate cancer$327,496
R34 · FY2024 · CA
Advanced Training in Urologic Oncology$246,023
T32 · FY2024 · CA
Physician dispensing of oral specialty drugs for advanced prostate cancer and its implications for patients$94,664
R01 · FY2024 · CA
Leveraging the ESRD Treatment Choices model to understand the benefits of home versus in-center dialysis$674,010
R01 · FY2023 · DK · contact PI
Real-world effectiveness of preventive pharmacological therapy for patients with kidney stones$590,232
R01 · FY2023 · DK · contact PI
Aligning financial incentives to promote rational use of active surveillance for prostate cancer$559,381
R01 · FY2023 · CA · contact PI
Physician dispensing of oral specialty drugs for advanced prostate cancer and its implications for patients$530,886
R01 · FY2023 · CA
Primary care involvement in End Stage Renal Disease Seamless Care Organizations (ESCOs) and the quality and costs of care for patients on chronic dialysis$399,999
R01 · FY2023 · HS · contact PI
Effects of integration of advanced practice providers into surgical group practice$396,696
R01 · FY2023 · HS
Advanced Training in Urologic Oncology$319,635
T32 · FY2023 · CA
Physician dispensing of oral specialty drugs for advanced prostate cancer and its implications for patients$44,922
R01 · FY2023 · CA
Real-world effectiveness of preventive pharmacological therapy for patients with kidney stones$608,867
R01 · FY2022 · DK · contact PI
Aligning financial incentives to promote rational use of active surveillance for prostate cancer$578,436
R01 · FY2022 · CA
Training Core$522,056
TL1 · FY2022 · DK · contact PI
Primary care involvement in End Stage Renal Disease Seamless Care Organizations (ESCOs) and the quality and costs of care for patients on chronic dialysis$399,999
R01 · FY2022 · HS · contact PI
Primary care involvement in End Stage Renal Disease Seamless Care Organizations (ESCOs) and the quality and costs of care for patients on chronic dialysis$400,000
R01 · FY2021 · HS · contact PI
Impact of urologist practice organization and health policy on prostate cancer treatment, overtreatment and spending$327,954
R01 · FY2021 · HS · contact PI
Primary care involvement in End Stage Renal Disease Seamless Care Organizations (ESCOs) and the quality and costs of care for patients on chronic dialysis$400,000
R01 · FY2020 · HS · contact PI
Impact of urologist practice organization and health policy on prostate cancer treatment, overtreatment and spending$327,954
R01 · FY2020 · HS
Impact of urologist practice organization and health policy on prostate cancer treatment, overtreatment and spending$327,954
R01 · FY2019 · HS
Impact of urologist practice organization and health policy on prostate cancer treatment, overtreatment and spending$320,154
R01 · FY2018 · HS
Impact of urologist practice organization and health policy on prostate cancer treatment, overtreatment and spending$396,240
R01 · FY2017 · HS
Impact of Urologist Practice Structure on Prostate Cancer Care$362,271
R01 · FY2016 · CA
Impact of Urologist Practice Structure on Prostate Cancer Care$362,271
R01 · FY2015 · CA
Impact of Urologist Practice Structure on Prostate Cancer Care$422,156
R01 · FY2014 · CA
Impact of Urologist Practice Structure on Prostate Cancer Care$480,372
R01 · FY2013 · CA
Optimizing use of androgen deprivation therapy for prostate cancer$234,507
R01 · FY2010 · CA · contact PI
Optimizing use of androgen deprivation therapy for prostate cancer$248,153
R01 · FY2009 · CA · contact PI
GnRH Agonists For Prostate Cancer: Role of the Urologist$168,866
R01 · FY2007 · CA · contact PI
GnRH Agonists For Prostate Cancer: Role of the Urologist$179,581
R01 · FY2006 · CA · contact PI
GnRH Agonists For Prostate Cancer: Role of the Urologist$10,632
R01 · FY2006 · CA · contact PI
GnRH Agonists For Prostate Cancer: Role of the Urologist$194,790
R01 · FY2005 · CA